Tsuyoshi Shiga
   Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine
   Position   Visiting Professor
Language English
Title Renal Function and the Prognostic Impact of Renin-angiotensin-aldosterone System Inhibitors for Heart Failure Patients: An Analysis of HIJ-HF II Study
Conference The 83rd Annual Scientific Meeting of the Japanese Circulation Society (JCS2019)
Promoters Japanese Circulation Society
Conference Type Nationwide Conferences
Presentation Type Speech
Lecture Type General
Publisher and common publisher◎SUZUKI Keisuke, OYABU Kenjiro, SUZUKI Atsushi, MATSUI Yuko, NAGARA Kimiko, HARUKI Shintaro, KIKUCHI Noriko, HATTORI Hidetoshi, WATANABE Erisa, SUZUKI Tsuyoshi, SHIGA Tsuyoshi, HAGIWARA Nobuhisa
Date 2019/03/29
Venue
(city and name of the country)
Yokohama, JAPAN
Summary *Featured Research Session 4 (HF/CM) Heart Failure, Cardiomyopathy (Clinical)
Angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB) reduce mortality and morbidity in patients with heart failure (HF). The aim of this study was to assess the impact of ACE-I or ARB on mortality among HF
patients with and without renal dysfunction. After the exclusion of patients receiving regular hemodialysis, 536 HF patients discharged alive (age: 70±15 years, 34% female) from a multicenter hospital-based cohort consisted of HF patients between 2013 and 2014 were studied. Renal dysfunction was defined estimated glomerular filtration rate <60 mL/min/1.73 m2. During 17±10 months follow-up, there was a tendency that the mortality rate was higher in patients with renal dysfunction compared without renal dysfunction (18% vs. 13%). Although the mortality was significantly lower in ACE-I/ARB patients than nonACE-I/ARB patients among patients without renal dysfunction (Figure A), there was no difference in mortality between ACE-I/ARB and non-ACE-I/ARB patients among patients with renal dysfunction (Figure B). The effect of ACE-I/ARB on mortality might be difference in HF patients with and without renal dysfunction.